Business Model Breakdown
How Terns Pharmaceuticals Inc Makes Money
TERN
Market Cap
$6.1B
Employees
59
The Short Version
Terns Pharmaceuticals Inc. was a clinical-stage biopharmaceutical company focused on developing a pipeline of small-molecule product candidates for the treatment of oncology and metabolic diseases. It operated by conducting preclinical and clinical trials to advance its drug candidates, with the ultimate goal of commercializing successful therapies. Revenue generation was primarily through upfront payments and milestones from collaboration agreements, as it had no commercialized products. Its business model was highly dependent on successful drug development and regulatory approvals. As of May 5, 2026, Terns has been acquired by Merck and operates as a wholly-owned subsidiary, with its pipeline integrated into Merck's R&D efforts.
Where the Revenue Comes From
Collaboration and license agreements (e.g., upfront payments, milestone payments) - historically, this was its primary revenue source as a clinical-stage company.
Who buys: Historically, its customers were larger pharmaceutical partners for collaborations. Ultimately, its potential end-users would have been patients suffering from diseases like chronic myeloid leukemia and obesity, through healthcare providers.
Why It Works (Competitive Advantages)
- ✔Not applicable for public equity analysis; Terns' assets are now part of Merck's portfolio.
Economic Moat: None
What Our Analysis Says
DVR Score as of May 9, 2026
Score Change Explanation: The score has been maintained at an extremely low level (0/100, down from the previous 1/100) to reflect the definitive and irreversible change in Terns Pharmaceuticals' status. On May 5, 2026, Merck completed its acquisition of TERN for $53.00 per share, and the company has since been delisted from Nasdaq. This corporate action entirely eliminates TERN's independent existence as a public company and, consequently, any possibility of it generating 10x growth for public shareholders. The original criteria of future market leadership, competitive advantages, and strategic positioning for independent 10x growth are no longer applicable whatsoever. The stock no longer trades, rendering it a non-investment for new public equity participants seeking growth.